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Abstract 
Extramedullary plasmacytomas are tumors of monoclonal plasma cells arising within soft 
tissue that uncommonly occur in multiple myeloma patients. While sporadic 
development of these tumors at cutaneous trauma sites, including venous catheter 
access sites, has been reported, interventional radiologists seldom encounter this 
disease. Herein, we describe a case of metastatic subcutaneous plasmacytoma 
precipitated by tunneled central venous catheter insertion in a male patient undergoing 
stem cell therapy for treatment of multiple myeloma. In addition, we review the 
identification, diagnostic pitfalls, pathogenesis, and treatment of this rare entity. 
 
Introduction 
Extramedullary plasmacytomas, which are tumors of monoclonal plasma cells arising 
within soft tissue, represent an uncommon manifestation of multiple myeloma [1, 2]. 
These lesions are present in approximately 7% of multiple myeloma patients at the time of 
diagnosis, and occur in an additional 6–7% of patients over the course of their disease [1, 
2]. The primary site of involvement is the upper aerodigestive tract [3], and dermatologic 
manifestations of multiple myeloma are rare [4]. Cutaneous plasmacytomas generally 
result from direct spread from underlying bone or hematogenous spread in patients with 
high primary disease burden [5, 6]. While sporadic occurrence at venous catheter access Case Rep Oncol 2011;4:315–322 
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sites has been described [7, 8], medical oncologists and interventional radiologists rarely 
encounter this disease. As such, identification may be challenging, and lack of recognition 
may lead to misdiagnosis and unnecessary interventions. Herein, we describe a case of 
metastatic subcutaneous plasmacytoma that developed as a result of tunneled central 
venous catheter insertion in a man undergoing stem cell therapy for treatment of multiple 
myeloma, and highlight the recognition, diagnostic pitfalls, pathogenesis, and 
management of this entity. 
Case Report 
A 50-year-old Caucasian man with a past medical history notable for hypertension, high cholesterol, 
peripheral vascular disease, and coronary artery disease presented to medical attention in November 
2009 with progressive neck pain. A CT scan of his cervical spine revealed a lytic lesion in the C2 
vertebral body. Further diagnostic workup included a skeletal survey, which showed additional scattered 
lytic lesions in the right femur, skull, and multiple ribs. Subsequent bone marrow biopsy revealed 90% 
plasma cells with hyperdiploid cytogenetics, compatible with a diagnosis of multiple myeloma, staged as 
3a. Initial treatment consisted of external beam radiation therapy for the C2 vertebral lesion, followed 
by systemic chemotherapy using bortezomib (Velcade; Millennium Pharmaceuticals, Cambridge, Mass., 
USA) and dexamethasone. The patient completed 3 chemotherapeutic cycles by the end of December 
2009. Lenalidomide (Revlimid; Celgene Corporation, Summit, N.J., USA) was then added to the 
chemotherapy regimen in January 2010, and the patient completed 4 cycles by late May 2010. Of note, a 
left orbital plasmacytoma that had developed during the patient’s chemotherapy course was also treated 
with radiation therapy. 
Although response to therapy was initially favorable, the patient developed a florid systemic relapse 
in July 2010 and became transfusion dependent. Vincristine, doxorubicin, and dexamethasone 
chemotherapy was restarted in early August 2010, with cyclophosphamide initiated in early September 
2010 due to progressive disease and persistent anemia. The patient responded favorably to 
cyclophosphamide and received 2 cycles of cyclophosphamide, dexamethasone, etoposide, and cisplatin 
in October 2010. Repeat bone marrow biopsy in late October 2010 revealed no evidence of myeloma. 
At this point, given the patient’s young age and the extent of his disease, autologous stem cell 
transplantation was recommended. The patient agreed for this therapy and was referred to 
interventional radiology in early November 2010 for tunneled central venous catheter insertion for 
transplant therapy. Catheter insertion was performed using standard techniques, and no prophylactic 
antibiotics were administered. Direct ultrasound guidance was used to guide access into the left internal 
jugular vein using a 21-gauge needle (Micropuncture Introducer Set; Cook Medical, Bloomington, Ind., 
USA). The percutaneous access was dilated to accept a 5-French introducer (Micropuncture Introducer 
Set; Cook Medical), through which a 0.035-inch stiff guide wire was advanced into the inferior vena 
cava under fluoroscopic guidance. Attention was then turned to the left chest wall, where a 5-mm 
incision was made. A triple-lumen catheter (TriFusion; C. R. Bard, Murray Hill, N.J., USA) was 
tunneled from this location to the venotomy site. After serial tract dilation, the catheter was then 
introduced into the central venous system (fig. 1) and was secured to the skin with suture. 
The patient subsequently underwent melphalan conditioning, followed by stem cell transplantation 
in early December 2010. He tolerated the treatment well, and his hospital course was complicated only 
by neutropenic fever treated with intravenous antibiotics. The patient showed response to the stem cell 
transplant, and the tunneled central venous catheter was removed without incident in mid-December 
2010 by standard local anesthesia, blunt dissection, and gentle traction. The skin at the catheter entry 
site was approximated using adhesive strips (Steri-Strips; 3M, Maplewood, Minn., USA). The patient’s 
disease course was then unremarkable until he returned to the interventional radiology clinic in mid-
February 2011 with complaint of a painful and enlarging subcutaneous nodule located at the exact site 
of the previous central venous catheter insertion in the left chest. 
Clinical examination and ultrasound of the mass were performed, and a diagnosis of mature 
hematoma was initially entertained. The patient was therefore reassured and instructed to return to 
clinic 1 week later for reassessment. Upon returning to clinic, however, the mass had enlarged to Case Rep Oncol 2011;4:315–322 
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2 × 2 cm (fig. 2), and the decision was made to pursue incision and drainage in order to evacuate any 
hematoma and to ligate any potentially oozing subcutaneous vessels. In the angiography suite, the left 
chest was prepped and draped. After local anesthesia was applied, a 2-cm incision was made along the 
inferior aspect of the mass. Open visual assessment of the lesion was not consistent with hematoma, and 
as such, after consultation with the patient’s medical oncologist, two open biopsy samples were 
obtained. The incision was then closed in two layers using 3-0 and 5-0 Vicryl sutures (Ethicon, Inc., 
Somerville, N.J., USA). The final pathology report indicated that the mass was an extramedullary 
plasmacytoma (fig. 3). The patient subsequently received palliative radiation to the chest lesion and 
blood transfusions for treatment of ongoing anemia. He is alive and doing well at the time of this report. 
Institutional review board approval is not required for single retrospective case studies at the authors’ 
institutions. 
Discussion 
Multiple myeloma is a disease resulting from the clonal proliferation of malignant 
plasma cells [9]. This neoplasm accounts for 13% of hematologic cancers [9] and typically 
involves the skeletal marrow. Extramedullary plasmacytoma is a manifestation of multiple 
myeloma in which a discrete mass of neoplastic monoclonal plasma cells forms in soft 
tissue. The diagnosis of extramedullary plasmacytoma is established on the basis of tissue 
biopsies, although some patients may have an elevated serum or urine monoclonal 
protein level. 
Extramedullary relapse of multiple myeloma is uncommon, occurring with an 
incidence of 6–7% [1, 2]. The rate of recurrence is increased after autologous bone 
marrow transplantation as compared to conventional chemotherapy [10]. The oral cavity 
and upper respiratory tract are the most common sites of development, accounting for 
80% of cases [3]. Few cases of cutaneous extramedullary plasmacytoma have been 
reported, and growth at sites of trauma, including central venous access sites, as in our 
case, is very rare. Kerob et al. [7] described the identification of cutaneous lesions in 2 
patients who received chemotherapy through a central venous catheter, and Rosenblum et 
al. [8] reported multiple subcutaneous plasmacytomas localized to areas of previous 
trauma, including two central venous catheter access sites. 
Systemic tumor spread is a complex multistep process. The occurrence of tumor 
implants at surgical wound sites is related to both local and systemic etiologic factors and 
may be predisposed to by direct wound contamination, tumor manipulation and 
aerosolization, and changes in host immune response, among other causes [11]. Multiple 
theories have been proposed to explain the pathophysiology of plasmacytoma 
development at trauma sites. A dominant theory relates to survival and clonal selection of 
myeloma cells expressing the CXCR-4 chemokine receptor after high-dose induction 
chemotherapy [2]. The ligand for this receptor, stromal cell-derived factor-1 (SDF-1), is a 
highly potent immune cell (mononuclear cell, mast cell, and T-cell) attractant [12–14] 
expressed in areas of trauma and inflammation. When a traumatic insult to the cutaneous 
or subcutaneous tissues results in increased local SDF-1 levels, preferential trafficking of 
CXCR-4-positive cells to these areas may occur [12]. Subsequently, the release of various 
inflammatory cytokines may enable the proliferation of recruited plasma cells, resulting in 
focal tumor formation [15]. To the best of our knowledge, there is no association between 
needle or vascular access device caliber and the formation of local tumor implantation. 
Although an infrequent occurrence, medical oncologists and interventional 
radiologists should be aware of the potential for plasmacytoma formation at central Case Rep Oncol 2011;4:315–322 
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venous access sites or sites of other percutaneous intervention in order to avoid 
misdiagnosis and unnecessary procedures. Multiple myeloma patients are periodically 
referred to interventional radiology for catheter access prior to stem cell therapy or other 
procedures, and intermittent interaction with these patients is likely in routine 
interventional radiology practice. In our case, the metastatic tumor was initially mistaken 
to represent a mature hematoma, which may occur after catheter removal in a stem cell 
transplant patient. However, clues that may have led to the correct diagnosis sooner were 
delayed lesion development after catheter removal and considerable focal pain at the 
abnormal site. Authors reporting cases of port site breast cancer and leukemic implants 
have advocated prompt biopsy of persistent chest wall masses [16, 17]. Although a 
percutaneous biopsy would have still been appropriate if plasmacytoma had been an 
earlier diagnostic consideration, a 2–3-cm incision may have been avoided in lieu of a 
small needle puncture. For these reasons, it is important to consider extramedullary 
plasmacytoma in the differential diagnosis of superficial masses in high-risk patients with 
a history of multiple myeloma. 
While cutaneous plasmacytomas are typically associated with favorable 5-year survival 
rates [18], some reported cases of cutaneous extramedullary plasmacytoma relapse 
indicate a rapid decline in the patients’ medical condition and eventual expiration [7, 8]. 
Therapy often includes a combination of chemotherapy, local radiation therapy and/or 
surgical resection [19]. Because there are so few case reports involving the treatment of 
cutaneous plasmacytomas, however, there are currently no strong treatment 
recommendations. Future reports will continue to shed light on this rare disease. 
Disclosure Statement 





 Case Rep Oncol 2011;4:315–322 
DOI: 10.1159/000330044 
Published online: 
June 30, 2011 
© 2011 S. Karger AG, Basel
ISSN 1662–6575 






Fig. 1. Fluoroscopic spot image after tunneled central venous catheter insertion for stem cell therapy 
shows the newly placed left-sided triple-lumen catheter with the tip (arrowhead) appropriately 
positioned in the upper right atrium. Note that a right-sided central venous catheter was also present. 
 
 Case Rep Oncol 2011;4:315–322 
DOI: 10.1159/000330044 
Published online: 
June 30, 2011 
© 2011 S. Karger AG, Basel
ISSN 1662–6575 






Fig. 2. Photograph of the patient’s chest reveals a subcutaneous mass (demarcated by white 
arrowheads) with overlying erythema located at the skin entry site of the previously tunneled central 
venous catheter. Note the healing incision from the subsequent open biopsy (demarcated by black 
arrowheads). Inset shows that the nodule measures 2 × 2 cm. 
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Fig. 3. High magnification (×40) of a HE-stained slide (left) showing sheets of malignant plasma cells 
with eccentrically located nuclei and prominent nucleoli. An immunoperoxidase-stained slide (right) 
which is CD138 positive in malignant plasma cells. 
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